Cerebrospinal fluid neurogranin: relation to cognition and neurodegeneration in Alzheimer's disease.

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Brain : a journal of neurology

• Publication date

  2015-11-01

• Fields of study

  Medicine, Psychology

• Identifiers
  DOI 10.1093/brain/awv267PMID 26373605PMCID PMC4643642
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Cerebrospinal fluid levels of the synaptic protein neurogranin correlates with cognitive decline in prodromal Alzheimer's disease

  2015cited by this paper
• Phase 3 trial of flutemetamol labeled with radioactive fluorine 18 imaging and neuritic plaque density.

  2015cited by this paper
• Diagnostic accuracy of CSF Ab42 and florbetapir PET for Alzheimer's disease

  2014cited by this paper
• Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria.

  2014cited by this paper
• Non-Alzheimer neurodegenerative pathologies and their combinations are more frequent than commonly believed in the elderly brain: a community-based autopsy series

  2013cited by this paper
• Amyloid deposition, hypometabolism, and longitudinal cognitive decline

  2012cited by this paper
• Neurogranin in cerebrospinal fluid as a marker of synaptic degeneration in Alzheimer's disease.

  2010cited by this paper
• Alzheimer disease.

  2010cited by this paper
• Mini Mental State

  2010cited by this paper
• Neurogranin, a link between calcium/calmodulin and protein kinase C signaling in synaptic plasticity

  2010cited by this paper
• Cerebrospinal fluid and plasma biomarkers in Alzheimer disease

  2010cited by this paper
• Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects

  2009influential reference
• Long‐term potentiation: two pathways meet at neurogranin

  2009cited by this paper
• The Alzheimer's disease neuroimaging initiative (ADNI): MRI methods

  2008influential reference
• Brain Glucose Hypometabolism and Oxidative Stress in Preclinical Alzheimer's Disease

  2008cited by this paper
• Synaptic alterations in CA1 in mild Alzheimer disease and mild cognitive impairment

  2007influential reference
• RC3/neurogranin, a postsynaptic calpacitin for setting the response threshold to calcium influxes

  2007cited by this paper
• Synaptic pathology in Alzheimer's disease: Relation to severity of dementia, but not to senile plaques, neurofibrillary tangles, or the ApoE4 allele

  2005influential reference
• Automatically parcellating the human cerebral cortex.

  2004cited by this paper
• Neurogranin/RC3 Enhances Long-Term Potentiation and Learning by Promoting Calcium-Mediated Signaling

  2004cited by this paper
• Neurotechnique Whole Brain Segmentation: Automated Labeling of Neuroanatomical Structures in the Human Brain

  2002cited by this paper
• Altered expression of synaptic proteins occurs early during progression of Alzheimer’s disease

  2001influential reference
• Involvement of neurogranin in the modulation of calcium/calmodulin-dependent protein kinase II, synaptic plasticity, and spatial learning: a study with knockout mice.

  2000cited by this paper
• Identification of synaptic vesicle, pre‐ and postsynaptic proteins in human cerebrospinal fluid using liquid‐phase isoelectric focusing

  1999cited by this paper
• RC3/neurogranin, a postsynaptic calpacitin for setting the response threshold to calcium influxes.

  1997cited by this paper
• Loss of the Presynaptic Vesicle Protein Synaptophysin in Hippocampus Correlates with Cognitive Decline in Alzheimer Disease

  1997influential reference
• Neurogranin in the development of the rat telencephalon.

  1996cited by this paper
• Synaptotagmin, a synaptic vesicle protein, is present in human cerebrospinal fluid: a new biochemical marker for synaptic pathology in Alzheimer disease?

  1996cited by this paper
• Deterioration threshold of synaptic morphology in aging and senile dementia of Alzheimer's type.

  1996influential reference
• Characterization of a 7.5-kDa protein kinase C substrate (RC3 protein, neurogranin) from rat brain.

  1993cited by this paper
• Purification and characterization of a brain-specific protein kinase C substrate, neurogranin (p17). Identification of a consensus amino acid sequence between neurogranin and neuromodulin (GAP43) that corresponds to the protein kinase C phosphorylation site and the calmodulin-binding domain.

  1991cited by this paper
• Neurogranin: immunocytochemical localization of a brain-specific protein kinase C substrate

  1990cited by this paper
• Synapse loss in frontal cortex biopsies in Alzheimer's disease: Correlation with cognitive severity

  1990cited by this paper
• A quantitative morphometric analysis of the neuronal and synaptic content of the frontal and temporal cortex in patients with Alzheimer's disease.

  1987cited by this paper
• A new rating scale for Alzheimer's disease.

  1984cited by this paper
• “Mini-mental state”: A practical method for grading the cognitive state of patients for the clinician

  1975cited by this paper

• Synaptic and cytoskeletal CSF signatures of motor neuron disease: the role of cyclase-associated protein 2.

  2026cites this paper
• A multi-target therapeutic framework for Alzheimer's disease: an integrative mechanistic review.

  2026cites this paper
• Diagnostic and prognostic utility of serum β-synuclein in Alzheimer's disease: a longitudinal cohort study.

  2026cites this paper
• Charting the research frontier for viral infections, immunomodulation, and dementia: a perspective on synaptic biomarkers as essential clinical trial endpoints

  2026cites this paper
• Cerebrospinal fluid levels of neurogranin and YKL-40 in mild cognitive impairment due to Alzheimer's disease or vascular dementia

  2026cites this paper
• The Potential Role of Neurogranin in Alzheimer's Disease.

  2025influential citation
• Acute restraint stress and epinephrine administration disrupt cognitive and emotional functions in male rats via modulation of proinflammatory cytokines, MCT-2, and neurogranin.

  2025cites this paper
• 7-α-O-Methylmorroniside ameliorated brain injury in 5×FAD mice by regulating the gut microbiome and NMDAR2B

  2025cites this paper
• Influence of co-pathology on CSF and plasma synaptic markers SNAP25 and VAMP2 in Alzheimer’s disease and Parkinson’s disease

  2025cites this paper
• Comparison of CSF neurofilament light chain and total tau as neurodegeneration markers: Associations with synaptic markers and cognitive outcomes.

  2025cites this paper
• The Cooperation of Neurogranin with Calmodulin Promotes the Treatment of Aging-Related Diseases via Regular Exercise

  2025cites this paper
• Potential diagnostic markers in Alzheimer's disease: current perspectives and future directions.

  2025cites this paper
• Synaptic protein CSF levels relate to memory scores in individuals without dementia

  2025cites this paper
• Neurogranin in cerebrospinal fluid as a marker of synaptic dysfunction in hip fracture patients with delirium: a multicentre cross-sectional study

  2025cites this paper
• The increase in TDP-43 and neurogranin blood levels at different stages of cognitive impairment in the elderly people: A cross-sectional study

  2025cites this paper
• Marqueurs biologiques des maladies neurodégénératives

  2025cites this paper
• Fluid biomarkers for neurodegenerative diseases: a comprehensive update

  2025cites this paper
• Cerebrospinal fluid NPTX2 and [18F]FDG PET track serotonergic vulnerability to neurodegeneration in prodromal Alzheimer’s disease

  2025cites this paper
• Amyloid solutions: lecanemab, gantenerumab, and donanemab in the treatment of Alzheimer's disease

  2025cites this paper
• Proteomic Analysis of the Low Molecular Mass Fraction of Newly Diagnosed and Recurrent Glioblastoma CUSA Fluid: A Pilot Investigation of the Peptidomic Profile

  2025cites this paper
• A phase 2A/B randomized trial of metabolic modulators intranasal insulin and empagliflozin for MCI and early AD

  2025cites this paper
• Cerebrospinal Fluid Biomarkers of Alzheimer Disease

  2025cites this paper
• Biofluid biomarker changes following treatment with sabirnetug (ACU193) in INTERCEPT-AD, a phase 1 trial in early Alzheimer's disease

  2025cites this paper
• Synaptic dysfunction and glial activation markers throughout aging and early neurodegeneration: a longitudinal CSF biomarker-based study

  2025cites this paper
• Marcatori biologici delle malattie neurodegenerative

  2025cites this paper
• From Amyloid to Synaptic Dysfunction: Biomarker-Driven Insights into Alzheimer’s Disease

  2025cites this paper
• CSF total tau as a proxy of synaptic degeneration

  2025cites this paper
• BACE1 Inhibitors for Alzheimer’s Disease: Current Challenges and Future Perspectives

  2024cites this paper
• Neuroinflammation, cerebrovascular dysfunction and diurnal cortisol biomarkers in a memory clinic cohort: Findings from the Co-STAR study

  2024cites this paper
• Polygenic hazard score predicts synaptic and axonal degeneration and cognitive decline in Alzheimer's disease continuum.

  2024cites this paper
• The Diagnostic Value of Cerebrospinal Fluid Neurogranin in Neurodegenerative Diseases

  2024cites this paper
• Comment on "Relationships between muscle strength, lung function, and cognitive function in Chinese middle-aged and older adults: A study based on the China health and retirement longitudinal study (CHARLS)": Subtitle: Muscle strength, lung function, and cognitive function.

  2024cites this paper
• Viral-mediated increased hippocampal neurogranin modulate synapses at one month in a rat model of controlled cortical impact

  2024cites this paper
• Association of Neurogranin and BACE1 With Clinical Cognitive Decline in Individuals With Subjective Cognitive Decline.

  2024cites this paper
• A multifactorial lens on risk factors promoting the progression of Alzheimer's disease.

  2024cites this paper
• Clarifying the association of CSF Aβ, tau, BACE1, and neurogranin with AT(N) stages in Alzheimer disease

  2024cites this paper
• CSF neurogranin levels as a biomarker in Alzheimer’s disease and frontotemporal lobar degeneration: a cross-sectional analysis

  2024cites this paper
• Exploring Intrinsic Disorder in Human Synucleins and Associated Proteins

  2024cites this paper
• Monitoring synaptic pathology in Alzheimer’s disease through fluid and PET imaging biomarkers: a comprehensive review and future perspectives

  2024cites this paper
• Fluid Biomarker Changes After Amyloid-β-Targeting Drugs.

  2024cites this paper
• Altered Cerebrospinal Fluid Neurofilament Light Chain but Not Neurogranin Levels Are Associated with Response to Ocrelizumab Treatment in Relapsing-Remitting Multiple Sclerosis: A Preliminary Study

  2024cites this paper
• Alzheimer’s disease and its treatment–yesterday, today, and tomorrow

  2024cites this paper
• Evaluation of neurogranin levels in a rat model of diffuse axonal injury.

  2024cites this paper
• Tau pathology is associated with synaptic density and longitudinal synaptic loss in Alzheimer’s disease

  2024cites this paper
• Associations of Serum Isoleucine with Mild Cognitive Impairment and Alzheimer’s Disease

  2024cites this paper
• Alzheimer's Disease Biomarker Analysis Using Targeted Mass Spectrometry

  2024cites this paper
• The Clinical Aspects of COVID and Alzheimer’s Disease: A Round-Up of Where Things Stand and Are Headed

  2024cites this paper
• A genetic and proteomic comparison of key AD biomarkers across tissues

  2024cites this paper
• Mitochondrial dysfunction is associated with cognitive impairment in adults with OSA without dementia.

  2024cites this paper
• CSF protein ratios with enhanced potential to reflect Alzheimer’s disease pathology and neurodegeneration

  2024cites this paper
• Cerebrospinal fluid in the differential diagnosis of Alzheimer’s disease: an update of the literature

  2024cites this paper
• Synaptic protein CSF levels relate to memory scores in individuals without dementia

  2024cites this paper
• High CSF neurogranin level is related to lifetime reports of passive suicidal ideation in a population-based sample of older adults.

  2024cites this paper
• CSF levels of brain-derived proteins correlate with brain ventricular volume in cognitively healthy 70-year-olds

  2024cites this paper
• Cerebrospinal fluid biomarkers of axonal and synaptic degeneration in a population-based sample

  2023cites this paper
• Amyloid β-based therapy for Alzheimer’s disease: challenges, successes and future

  2023cites this paper
• Modern Approaches to the Diagnosis of Cognitive Impairment and Alzheimer’s Disease: A Narrative Literature Review

  2023cites this paper
• Proteomics analysis of prefrontal cortex of Alzheimer’s disease patients revealed dysregulated proteins in the disease and novel proteins associated with amyloid-β pathology

  2023cites this paper
• Neuroprotective Effects of a Multi-Herbal Extract on Axonal and Synaptic Disruption in Vitro and Cognitive Impairment in Vivo

  2023cites this paper
• Required improvements for cerebrospinal fluid-based biomarker tests of Alzheimer’s disease

  2023cites this paper
• Emerging Alzheimer’s disease therapeutics: promising insights from lipid metabolism and microglia-focused interventions

  2023cites this paper
• Cerebrospinal fluid NPTX2 changes and relationship with regional brain metabolism metrics across mild cognitive impairment due to Alzheimer's disease

  2023cites this paper
• The Critical Role of Biomarkers for Drug Development Targeting the Biology of Aging

  2023cites this paper
• Detecting Early Cognitive Decline in Alzheimer’s Disease with Brain Synaptic Structural and Functional Evaluation

  2023cites this paper
• Decreased DHA‐containing phospholipids in the neocortex of dementia with Lewy bodies are associated with soluble Aβ42, phosphorylated α‐synuclein, and synaptopathology

  2023cites this paper
• CSF sphingomyelin metabolites in Alzheimer's disease, neurodegeneration, and neuroinflammation

  2022cites this paper
• Neurobiological Highlights of Cognitive Impairment in Psychiatric Disorders

  2022cites this paper
• PM2.5 exposure associated with microbiota gut-brain axis: Multi-omics mechanistic implications from the BAPE study

  2022cites this paper
• New developments of biofluid‐based biomarkers for routine diagnosis and disease trajectories in frontotemporal dementia

  2022cites this paper
• Synaptic Proteins as Fluid Biomarkers in Alzheimer’s Disease: A Systematic Review and Meta-Analysis

  2022cites this paper
• Synaptic degeneration in Alzheimer disease

  2022cites this paper
• Stable cerebrospinal fluid neurogranin and β-site amyloid precursor protein cleaving enzyme 1 levels differentiate predementia Alzheimer’s disease patients

  2022cites this paper
• CSF Biomarkers of Alzheimer Disease in Patients With Concomitant α-Synuclein Pathology

  2022cites this paper
• Subtle Differences in Cognition in 70-Year-Olds with Elevated Cerebrospinal Fluid Neurofilament Light and Neurogranin: A H70 Cross-Sectional Study

  2022cites this paper
• Combined Effects of Synaptic and Axonal Integrity on Longitudinal Gray Matter Atrophy in Cognitively Unimpaired Adults

  2022cites this paper
• Cerebrospinal fluid growth-associated protein 43 levels in patients with progressive and stable mild cognitive impairment

  2022cites this paper
• Research Progress of Biomarkers for the Di-agnosis of Alzheimer’s Disease

  2022cites this paper
• Predicting conversion from mild cognitive impairment to Alzheimer’s disease with multimodal latent factors

  2022cites this paper
• P-tau subgroups in AD relate to distinct amyloid production and synaptic integrity profiles

  2022cites this paper
• Exploring the brain metabolic correlates of process-specific CSF biomarkers in patients with MCI due to Alzheimer's disease: preliminary data.

  2022cites this paper
• Alzheimer’s disease: a scoping review of biomarker research and development for effective disease diagnosis

  2022cites this paper
• Pathophysiology of neurodegenerative diseases: An interplay among axonal transport failure, oxidative stress, and inflammation?

  2022cites this paper
• Associations between cerebrospinal fluid markers and cognition in ageing and dementia: A systematic review

  2022cites this paper
• Fluid Biomarkers in Alzheimer’s Disease and Other Neurodegenerative Disorders: Toward Integrative Diagnostic Frameworks and Tailored Treatments

  2022cites this paper
• The Neurochemistry of Alzheimer’s Disease: One of the Most Common Causes of Reduced Capability in the Adult Population

  2022cites this paper
• Advances in the development of new biomarkers for Alzheimer’s disease

  2022cites this paper
• CSF sphingomyelins in Alzheimer’s disease, neurodegeneration, and neuroinflammation

  2022cites this paper
• Proteomic Markers and Early Prediction of Alzheimer’s Disease

  2022cites this paper
• Relationship between cerebrospinal fluid neurodegeneration biomarkers and temporal brain atrophy in cognitively healthy older adults.

  2022influential citation
• Association of CSF GAP-43 With the Rate of Cognitive Decline and Progression to Dementia in Amyloid-Positive Individuals

  2022cites this paper
• Cerebrospinal Fluid Sphingomyelins in Alzheimer’s Disease, Neurodegeneration, and Neuroinflammation

  2022cites this paper
• The Worldwide Alzheimer's Disease Neuroimaging Initiative: ADNI‐3 updates and global perspectives

  2021cites this paper
• A Non-APOE Polygenic Risk Score for Alzheimer’s Disease Is Associated With Cerebrospinal Fluid Neurofilament Light in a Representative Sample of Cognitively Unimpaired 70-Year Olds

  2021cites this paper
• Neurofilament light as a biomarker of axonal degeneration in patients with mild cognitive impairment and Alzheimer's disease.

  2021cites this paper
• The associations of serum valine with mild cognitive impairment and Alzheimer’s disease

  2021cites this paper
• Neurogranin as a Reliable Biomarker for Synaptic Dysfunction in Alzheimer’s Disease

  2021cites this paper
• Biomarkers used in Alzheimer's Disease diagnosis, treatment, and prevention.

  2021cites this paper
• Preclinical and clinical biomarker studies of CT1812: A novel approach to Alzheimer's disease modification

  2021cites this paper
• The synaptic marker neurogranin as a disease state biomarker in Alzheimer’s disease: A systematic review and meta‐analysis

  2021influential citation
• The Prognostic Utility of CSF Neurogranin in Predicting Future Cognitive Decline in the Alzheimer's Disease Continuum: A Systematic Review and Meta-Analysis with Narrative Synthesis.

  2021cites this paper